|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-12-18
|
|
pubmed:abstractText |
The greatest decrease in mortality from cardiovascular disease (CAD) that can be achieved with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) is seen in patients with the highest risk for CAD, such as diabetics. Yet, there is evidence for inadequate use of drug therapies to achieve lipid goals. Our aims were to: (1) assess the prevalence of statin use in patients attending diabetic clinics and (2) correlate the use of statins with their risk and clinical status.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1590-3729
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
32-40
|
|
pubmed:meshHeading |
pubmed-meshheading:17174224-Adult,
pubmed-meshheading:17174224-Aged,
pubmed-meshheading:17174224-Cardiovascular Diseases,
pubmed-meshheading:17174224-Cholesterol, LDL,
pubmed-meshheading:17174224-Diabetes Mellitus, Type 2,
pubmed-meshheading:17174224-Diabetic Angiopathies,
pubmed-meshheading:17174224-Drug Utilization,
pubmed-meshheading:17174224-Female,
pubmed-meshheading:17174224-Humans,
pubmed-meshheading:17174224-Hydroxymethylglutaryl-CoA Reductase Inhibitors,
pubmed-meshheading:17174224-Male,
pubmed-meshheading:17174224-Middle Aged
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
The under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy.
|
|
pubmed:affiliation |
Department of Clinical and Experimental Medicine, University of Padova, School of Medicine, Via Giustiniani 2, 35128 Padova, Italy. angelo.avogaro@unipd.it
|
|
pubmed:publicationType |
Journal Article
|
